A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
NCT01413503
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Pheochromocytoma
Paraganglioma
Interventions
RADIATION:
131I-MIBG
Sponsor
University of California, San Francisco